About SmartZyme
SmartZyme is a company based in Herzliya (Israel) founded in 2013. SmartZyme has raised $4 million across 2 funding rounds from investors including Orbimed and VI Ventures. SmartZyme offers products and services including Assay Kits, ELISA Kits, Biology Cells, and Peptides. SmartZyme operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Herzliya, Israel
- SectorsHealthcare
- Website smzyme.com
- Social LinkedIn X
- Legal Name Smartzyme Biopharma, Ltd.
- Total Equity Funding$4M (USD)
in 2 rounds
- InvestorsOrbimed
& 1 more
Products & Services of SmartZyme
SmartZyme offers a comprehensive portfolio of products and services, including Assay Kits, ELISA Kits, Biology Cells, and Peptides.
Kits for biological testing and analysis in laboratories.
Kits for detecting proteins and antibodies in research.
Products for cell biology and culture applications.
Reagents used in protein research and experiments.
Funding Insights of SmartZyme
SmartZyme has successfully raised a total of $4M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $4M
- Total Rounds 2
- First Round $4M
(Oct 2015)
- Investors Count 2
All 2 funding rounds of SmartZyme with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2018 | – | Series B | – | Orbimed, VI Ventures | – |
| Oct 2015 | $4M | Series A | – | – |
2 investors in total: 2 institutional.
Investors in SmartZyme
SmartZyme has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Orbimed and VI Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
- | – | vi-ventures.com | - |
Investor details for SmartZyme
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of SmartZyme
1 people are tracked at SmartZyme (1 in leadership).
| Name | Role | Group |
|---|---|---|
Shilo Ben Zeev | CEO | Leadership |
Complete people profiles for SmartZyme
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of SmartZyme
3 dated milestones of SmartZyme across 5 years, from founding to its latest funding, stage changes and deals.
- Founded SmartZyme is founded.
- Funding First funding round of $4.0M.
- Funding Latest funding round, Series B,.
Competitors of SmartZyme
SmartZyme operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| gsk.com | 1715 | Brentford, United Kingdom | – | 90,913 | Developer of pharmaceuticals and vaccines for various therapeutic areas | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| synthego.com | 2012 | Redwood, United States | $459.75M | – | CRISPR-engineered cell and gene therapies are developed for research applications. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. | |
| lifeminetx.com | 2016 | Cambridge, United States | $300.07M | 85 | Developer of novel drugs from fungi via genome mining and recombinant overexpression |
Detailed competitors of SmartZyme
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Smartzyme
Complete news archive for SmartZyme
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to SmartZyme
10 companies that operate in the same segment as SmartZyme (Diabetes), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of devices for continuous glucose monitoring and manual insulin delivery | 2008 | San Diego, California, United States | USD 100.73 M | USD 1.02 B | 2,650 | |
Wearable glucose monitoring patches are provided for real-time data tracking. | 1999 | San Diego, California, United States | USD 52.5 M | USD 4.66 B | 10,300 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Small molecule drugs for various therapeutic areas are developed. | 1995 | United States | USD 165 M | USD 49.8 M | 103 | |
Implantable continuous glucose monitoring systems are provided for diabetes management. | 1996 | Germantown, United States | USD 175.46 M | USD 22.47 M | 117 | |
Developer of a closed-loop automated insulin delivery system | 2014 | Milpitas, California, United States | USD 214.51 M | – | 133 | |
Provider of workforce healthcare solutions | 2015 | New York, New York, United States | USD 107.87 M | – | 166 | |
Diabetes care and reversal programs are provided to patients. | 2021 | Bengaluru, Karnataka, India | USD 26.7 M | USD 5.07 M | 677 | |
Provider of smart devices for diabetes management for patients and doctors | 2014 | San Francisco, California, United States | USD 245.2 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 194 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about SmartZyme
SmartZyme was founded in 2013 and raised its 1st funding round 2 years after it was founded.
SmartZyme is headquartered in Herzliya, Israel. It is registered at Herzliya, Tel Aviv District, Israel.
SmartZyme is a funded company, having raised a total of $4M across 2 funding rounds to date. The company's 1st funding round was a Series A of $4M, raised on Oct 2015.
SmartZyme was founded in 2013 in Herzliya Pituach, Israel, within the biotechnology sector. The Provolution platform is employed for protein design and engineering to create enzymes with targeted characteristics. Focus is placed on the diabetes market, where an enzyme for enhanced glucose catalysis in test strips and the Go Patch Go system for on-demand blood glucose monitoring are being developed.
SmartZyme's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
SmartZyme offers Assay Kits, ELISA Kits, Biology Cells, and Peptides.
SmartZyme has 2 investors. Key investors include Orbimed, and VI Ventures.
SmartZyme operates through Smartzyme Biopharma, Ltd..